Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE known ✓ | P22303 | 1/20 | 0.32 |
| ▸ | HPGDS | O60760 | 1/20 | 0.49 |
| ▸ | BAZ2A | Q9UIF9 | 3/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.34 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.34 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.34 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.33 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.33 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.32 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.32 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4261249 | 0.99 | HPGDS (0.50) | HPGDSBAZ2AMEN1KMT2ANPY5R | |
| SCHEMBL2984450 | 0.77 | CHRM4 (0.36) | BAZ2ANPY5R | |
| SCHEMBL2984991 | 0.75 | ALDH1A1 (0.40) | BAZ2ANPY5RKCNH2TLR9TLR8 | |
| Bromide SCHEMBL2983628 | 0.75 | HPGDS (0.57) | HPGDSBAZ2AMEN1KMT2AGABRA1 | |
| Bromide SCHEMBL2984301 | 0.74 | HPGDS (0.60) | HPGDSBAZ2AMEN1KMT2AL3MBTL1 | |
| SCHEMBL4262100 | 0.73 | HPGDS (0.59) | HPGDSBAZ2AMEN1KMT2AGABRA1 | |
| SCHEMBL13422226 | 0.73 | HPGDS (0.52) | HPGDSBAZ2AMEN1KMT2AGABRA1 | |
| SCHEMBL1042507 | 0.73 | HPGDS (0.47) | HPGDSBAZ2AMEN1KMT2AGABRA1 | |
| SCHEMBL4265265 | 0.73 | HPGDS (0.61) | HPGDSBAZ2AMEN1KMT2AAOC3 | |
| Bromide SCHEMBL2973216 | 0.71 | HPGDS (0.76) | HPGDSBAZ2AMEN1KMT2AGABRA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7786143-B2 | Thiazolyl piperidine derivatives | HOFFMAN-LA ROCHE INC. (US) | 2010-08-31 | — | — | US | disclosed |
| EP-1945635-B1 | THIAZOLYL PIPERIDINE DERIVATIVES USEFUL AS H3 RECEPTOR MODULATORS | HOFFMANN LA ROCHE (CH) | 2009-05-06 | — | — | EP | disclosed |
| EP-1945635-A2 | THIAZOLYL PIPERIDINE DERIVATIVES USEFUL AS H3 RECEPTOR MODULATORS | F.HOFFMANN-LA ROCHE AG (CH) | 2008-07-23 | — | — | EP | disclosed |
| US-20070043083-A1 | Thiazolyl piperidine derivatives | HOFFMANN-LA ROCHE INC. | 2007-02-22 | — | — | US | disclosed |
| WO-2007020213-A2 | THIAZOLYL PIPERIDINE DERIVATIVES USEFUL AS H3 RECEPTOR MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-02-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043083-A1 | Thiazolyl piperidine derivatives | HRH3, HRH4, H1-3 | ACHE 3006/4885HPGDS 658/4885BAZ2A 445/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.